{"id":914134,"date":"2025-11-26T16:08:38","date_gmt":"2025-11-26T21:08:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/"},"modified":"2025-11-26T16:08:38","modified_gmt":"2025-11-26T21:08:38","slug":"vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/","title":{"rendered":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors"},"content":{"rendered":"
\n

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics\u2019 Board of Directors.<\/p>\n

“We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics\u2019 history as we prepare to launch a potential first-in-class dual BAFF\/APRIL inhibitor to transform the treatment of IgA nephropathy and other autoimmune diseases looking ahead,” said Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics. Jim brings exceptional expertise in commercial, public policy, and access that will be integral to our current stage of growth focusing on the immediate need to support an anticipated launch of atacicept for patients with IgA nephropathy.\u201d<\/p>\n

\u201cIt is a privilege to join the talented board members at Vera Therapeutics and be a part of the company\u2019s exciting growth trajectory. This is a transformational moment as the company prepares to launch atacicept next year, with goals to rapidly develop this high-potential therapy in other disease areas leading a paradigm shift in how patients with autoimmunity will be treated,\u201d said Jim Meyers, former Executive Vice President at Gilead Sciences and Senior Advisor at BCG. \u201cI am attracted to Vera Therapeutics\u2019 focus on changing the course of immunological diseases for patients who would otherwise be facing devastating outcomes. Vera Therapeutics is thoughtfully managing its transformation into a commercial organization while executing its strategy for atacicept as a potential pipeline in a therapy.\u201d<\/p>\n

Mr. Meyers has over thirty years of commercial leadership experience in the biopharmaceutical industry and worked at Gilead from 1996 until December 2021, most recently serving as a Senior Advisor. During his time at Gilead, he served as Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia, and Japan. Mr. Meyers led some of the most important and successful product launches in the history of the biopharmaceutical industry, most notably in the therapeutic areas of HIV and HCV. Over the course of more than two decades at Gilead, Mr. Meyers was part of a small group of executives who led the transition of the company from an innovative start-up to a profitable and successful global biopharmaceutical company that delivered more than $28 billion in revenue in 2024 and more importantly, has changed the course of disease in HIV and HCV. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with AstraZeneca. Most recently, Mr. Meyers served as President and Chief Executive Officer of IntraBio Ltd. from 2020 to 2024. Mr. Meyers currently serves on the Board of Directors of two public companies, Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc. He also remains a Senior Advisor at BCG to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.<\/p>\n

\n About Vera\u00a0Therapeutics\u00a0<\/strong>\n <\/p>\n

Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases.\u00a0Vera Therapeutics\u2019\u00a0mission is to advance treatments that target the source of disease in order to change the standard of care for patients.\u00a0Vera Therapeutics\u2019\u00a0lead product candidate is atacicept, a fusion protein self-administered\u00a0at home\u00a0as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including\u00a0IgAN\u00a0and lupus nephritis.\u00a0Beyond\u00a0IgAN, Vera Therapeutics is evaluating\u00a0additional\u00a0diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful.\u00a0In addition,\u00a0Vera\u00a0Therapeutics\u00a0holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell\u2013mediated diseases.\u00a0Vera Therapeutics\u00a0is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus,\u00a0which\u00a0can have devastating consequences in kidney transplant\u00a0recipients.\u00a0Vera Therapeutics\u00a0retains\u00a0all global developmental and commercial rights to atacicept, VT-109, and\u00a0MAU868. For more information, please visit\u00a0www.veratx.com<\/a>.\u00a0<\/strong><\/p>\n

\n Forward-looking Statements\u00a0<\/strong>\n <\/p>\n

Statements contained in this press release\u00a0regarding\u00a0matters, events or results that may occur in the future are\u00a0\u201cforward-looking statements\u201d\u00a0within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics\u2019 ability to launch a potential first-in-class dual BAFF\/APRIL inhibitor and transform the treatment of IgA nephropathy and other autoimmune diseases; the new board member\u2019s ability to support Vera Therapeutics\u2019 launch of atacicept; Vera Therapeutics\u2019 ability to rapidly develop atacicept in other disease areas and change how patients with autoimmunity will be treated; and the plans, commitments, aspirations and goals under the caption\u00a0\u201cAbout Vera Therapeutics\u201d. Words such as\u00a0\u201cbelieve,\u201d\u00a0\u201cexpect,\u201d\u00a0\u201cmay,\u201d\u00a0\u201cplan,\u201d\u00a0\u201cpotential,\u201d\u00a0\u201cwill\u201d\u00a0and similar expressions are intended to\u00a0identify\u00a0forward-looking statements. These forward-looking statements are based upon Vera Therapeutics\u2019\u00a0current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics\u2019\u00a0business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they\u00a0were made and are based on management\u2019s assumptions\u00a0and estimates as of\u00a0such\u00a0date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.\u00a0<\/p>\n

\n Investor Contact:<\/strong>
\n
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com<\/u><\/a><\/p>\n

\n Media<\/strong>
\n Contact:<\/strong>
\n
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics\u2019 Board of Directors. “We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics\u2019 history as we prepare to launch a potential first-in-class dual BAFF\/APRIL inhibitor to transform the treatment of IgA nephropathy and other autoimmune diseases looking ahead,” said Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics. Jim brings exceptional expertise in commercial, public policy, … <\/p>\n

Continue reading “Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-914134","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics\u2019 Board of Directors. “We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics\u2019 history as we prepare to launch a potential first-in-class dual BAFF\/APRIL inhibitor to transform the treatment of IgA nephropathy and other autoimmune diseases looking ahead,” said Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics. Jim brings exceptional expertise in commercial, public policy, … Continue reading "Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-26T21:08:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors\",\"datePublished\":\"2025-11-26T21:08:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/\"},\"wordCount\":1022,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/\",\"name\":\"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=\",\"datePublished\":\"2025-11-26T21:08:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk","og_description":"BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics\u2019 Board of Directors. “We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics\u2019 history as we prepare to launch a potential first-in-class dual BAFF\/APRIL inhibitor to transform the treatment of IgA nephropathy and other autoimmune diseases looking ahead,” said Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics. Jim brings exceptional expertise in commercial, public policy, … Continue reading \"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-26T21:08:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors","datePublished":"2025-11-26T21:08:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/"},"wordCount":1022,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/","name":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=","datePublished":"2025-11-26T21:08:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5MzA0MyM3MjkzNzk1IzIyMDc0Njk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vera-therapeutics-appoints-veteran-biotech-executive-james-r-meyers-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914134","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=914134"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/914134\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=914134"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=914134"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=914134"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}